Venture PartnerGM&C Life Sciences Fund
David is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he assesses investment opportunities and works with the Fund’s smaller investments to help companies successfully grow.
David is a well-known consultant and non-executive director/Chairman who co-founded DxS Diagnostics in 2000 to exploit a personalised medicine technology he had invented while with AstraZeneca Diagnostics. DxS was sold to Qiagen in September 2009 for in excess of £100m. Prior to DxS, David was Head of Technology Development at AstraZenica Diagnostics for four years where he led a team of up to 15 scientists working on new genome technologies.
David began his career as a Post-Doctoral Fellow with Warwick University Department of Biological Sciences, before joining Cambridge University Department of Medicine as a Senior Post-Doctoral Fellow where he researched the Genetics of Human Disease for six years.
David holds a First Class BSc in Genetics from the University of York and PhD in Biochemistry/Molecular Biology from the University of Leicester.
Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.
We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors. learn more
Binder House 7 Narborough Wood Park Desford Road Enderby Leicester LE19 4XT Tel: 0116 238 8200 email